Navigation Links
Study shows increase of hip and knee replacements in the US
Date:4/14/2008

With the graying of Americas Baby Boomer generation, arthritis is a growing health concern. Traditionally associated with the elderly, this common joint disease currently afflicts over 20 million men and women in the United States. To aggravate matters, arthritis is also prevalent among the overweightwhich describes nearly 65 percent of our nations adult population. Fortunately, treating the pain and disability of arthritis has been revolutionized by surgical joint replacements of the hips and knees. Unfortunately, as hip and knee replacements have become a more popular option, the toll on Medicare, private insurers and hospitals has escalated. Despite its huge implications for the healthcare system, the projected impact of joint replacements has attracted scant study.

To assess and address this issue, Sunny Kim, PhD, a researcher with the Robert Stempel School of Public Health at Florida International University, started with one of the largest databases of hospital procedures available: the Nationwide Inpatient Sample (NIS). Using the latest revision of international procedure coding, Dr. Kim identified joint replacement cases throughout the US and analyzed increases in surgeries and costs between 1997 and 2004. The April 2008 issue of Arthritis Care & Research (www.interscience.wiley.com/journal/arthritis) presents hard-hitting numbers to back her conclusion: the burden resulting from hip/knee joint replacement is not only substantial but also increasing at a steep rate.

Among Dr. Kims significant, distressing findings:

  • In 2004, approximately 431,485 primary knee replacements were performeda 53 percent increase from the year 2000. 225,900 primary hip replacements were performed in the USmarking a 37 percent increase for the same period.

  • In 1997, about 60 of primary hip replacements
    '/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , Dr. Redlener Applauds Historic Effort b...et Programs Are Lost in Final Health Care Reform ... The New England Journal of Medicine today pub...th care reform, co-authored by Irwin Redlener, M.D... National Center for Disaster Preparedness and Pro...
(Date:12/4/2009)...with knowledge of risks, many hesitate to take bre... Dec. 4 (HealthDay News) -- Worries about side eff...ican women at high risk for breast cancer are will...ase, a new study finds. , In an effort to infor... researchers at the University of Michigan Compreh...
(Date:12/4/2009)... , BOULDER, Colo., Dec. 4 ..., ON LOVE ,, Kathryn Budig, a prominent yoga te...e to healing--with a viewing of Twilight,s New Moo...nal.com: ,, http://www.elephantjournal.com/200...ournal.com: TASHI KING AND BREAST CANCER ,, el...
(Date:12/4/2009)... , JEFFERSON CITY, Mo., Dec. 4 /PRNewswire/ ...ctor Paul Crosetti, State Fire Marshal Randy Cole,...en,s fire safety program sponsored by Farmers call... safety day at the Missouri Capitol December 9. .../20080605/LATH062 ) ,, "The call for fire safet...
(Date:12/4/2009)...le who have had an ischemic stroke are at higher l... of medication can reduce that risk. One of the si...s, otherwise known as blood thinners, of which the...tudy to determine whether the use of antithromboti...r a seven-year period found that in each of the ye...
Breaking Medicine News(10 mins):Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Missouri Safety Day at the Capitol 2Health News:Are stroke survivors taking their medicine? 2
..., Dec. 3 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP...igational new,drug (IND) application to the U.S. F...und is an internally developed, orally-bioavailabl...r,patients in early 2008., "This IND submission i...
... N.Y., Dec. 3 Big A Drug Stores, Inc. has,selecte...al estate,solutions, to exclusively manage the dis...California. Big A Drug Stores, Inc. is a chain of ...gs,","Drug Fair," and "Drug Barn" (2 stores)., "W...
...APOLIS Although more and more drug advertisements...oximately $21 billion dollars that pharmaceutical ...is targeted to physicians, doctors in training (re...c. published in the December issue of the journal ...
...and PITTSBURGH, Dec. 2 Forest,Laboratories, Inc. ...ed that,Mylan has received an approvable letter fr...response to its New Drug Application (NDA) for,neb...icated that a recent inspection of,a backup manufa...
... communication with doctors and respect for role o...Y, Dec. 2 (HealthDay News) -- The death of a child...dparents, siblings, friends, even the child,s doct...ymptoms and stress of life-threatening illness -- ...
...ESTER, Ill. Hospital staff nurses who work extend...at work, or obtain less sleep are more likely to e... study published in the December 1 issue of the jo...ed from 895 full-time hospital staff nurses, who c...
Other Medicine News:Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 2Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 3Health News:Big A Drug Stores, Inc. Retains DJM Realty to Dispose of All Stores Operating Under the Names of Drug Emporium, Big A, Camelot, Drug Fair and Drug Barn 2Health News:Do medical schools affect the way future doctors interact with drug companies? 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 3Health News:Breaking Down Barriers to End-of-Life Care for Children 2Health News:Breaking Down Barriers to End-of-Life Care for Children 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 4
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 Dr...lts for prostate-specific antigen (PSA) recurrence...nts of biochemical recurrence rate in a Phase III ... for injection) or monthly leuprolide in prostate .... Prostate cancer patients who received FIRMAGON ...
(Date:12/3/2009)..., , NEW YORK, Dec. 3 Guid...rm, today announced the launch of their Sleep Apne...t monitors and projects trends and market share in...p Apnea Tracker captures actual patient usage for ...nited States from 15 different equipment providers...
(Date:12/3/2009)..., , SUNNYVALE, Calif., Dec. 3 /PRNewswire-..., a biopharmaceutical company focused on developin...ugs for the treatment of immune mediated diseases ...bcast and conference call on, Tuesday, December 8,...e and 8:00am Pacific Time) to discuss clinical dat...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 1Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 3ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 1ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 1CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 3
...AS, April 4, 2008 Data from five studies sponsore...d at the National Kidney,Foundation (NKF) 2008 Spr...e utilization studies involve PROCRIT(R) (Epoetin ...g utilization patterns and,costs of PROCRIT (EPO) ...s,related to chronic kidney disease (CKD) patients...
...iously-Stated Guidance Remains Unchanged, PRINCET...EDX ) today issued the following statement in resp... discontinuing its Phase 3 clinical,trial of front...LA-4,antibody (tremelimumab) compared to chemother...ey M. Nichol, M.B.Ch.B., Senior Vice President, Pr...
Other Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
HOME MULTI-DRUG TEST
SEDIPLAST ESR SYSTEM (with diluent)
SEDIPLAST ESR SYSTEM (without diluent)
Hemaprompt FG Gastric and Fecal Occult Blood Test
Medicine Products: